For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.
- Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Overcoming Bispecific Antibody Purification Challenges
Enhance the quality and safety of your BsAb therapeutics with a highly efficient with the right chromatography hydroxyapatite media.
-
Optimize T Cell Phenotype With One-Step Isolation And Activation
This comparative bench-scale study features active-release beads that could improve the reliability, consistency, and longevity of cell therapy treatments.
-
Cytokine-Mediated Inflammation In A Relevant Preclinical Model
Learn about a novel preclinical model and how it enables the study of cytokine-mediated barrier inflammation mechanisms as well as the efficacy of anti-inflammatory therapeutics.
-
Assessment Of Compound Toxicity Effects With High-Content Imaging
3D cellular models and bioprinting enhance drug safety predictions and offer precise spatial control. Explore an automated method for generating liver models to improve reproducibility and reliability in toxicity testing.
-
Advances In Flow-Through Technology To Enhance mAb Polishing
Optimize your monoclonal antibody purification with cutting-edge flow-through chromatography. Learn how POROS resins enhance polishing efficiency, improve aggregate removal, and streamline bioprocessing.
-
Fast And Scalable Fc Quantitation In Supernatants
In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.
-
Producing MSC-Derived Cell Therapies From Isolation To Large-Scale Expansion
Explore the journey of producing MSC-derived cell therapies, from initial isolation and expansion to final product formulation and storage, and learn how to optimize each step.
-
High-Yield Expression Of Complex Proteins From Stable Pools
This study presents the development of apoptosis-resistant CHO cell lines (DKO1 and DKO2), using electroporation technology, with the goal of enhancing biotherapeutic production.
-
How Blast Freezing Affects The Quality Of Bottled Drug Substance: Test Results And Insights
Uneven ice formation during bottle freezing creates a "Volcano Effect," pushing solutes into highly concentrated zones. This test-based study explains this risk to drug substance quality.
-
Improving Methodologies For iPSC Manufacturing And Differentiation
Learn how next-generation workflows are being developed to streamline iPSC manufacturing, enhance differentiation strategies, and overcome the hurdles of scalability and consistency.
NEWSLETTER ARCHIVE
- 03.04.26 -- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- 03.03.26 -- STREAM Edition: Breakthrough In HER2 Immunotherapy For PMO With Paul Romness
- 03.03.26 -- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- 03.02.26 -- Navigating Conflicting Raw Material Preferences With Your CDMO
- 02.27.26 -- Optimize Your Cell And Gene Therapy Manufacturing Workflows
- Powering AI And Synthetic Biology In Therapy Design
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections